Clinical trials: Genital Infection
Human Immunodeficiency Virus
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral…
- Trial name
- NCT01734850
- Testing
- Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Calimmune, Inc.
HIV Infections, Cancer
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
To determine the safety and efficacy of SNX-111 in controlling severe, chronic pain in cancer and AIDS patients.
- Conditions
- HIV Infections, Cancer, Pain
- Trial name
- NCT00002160
- Testing
- Ziconotide
- Where
- 44 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurex
Pneumonia, Pneumocystis Carinii, HIV Infections
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia
To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening…
- Trial name
- NCT00002103
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience
Bacterial Vaginoses
Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis
This is a randomized, double-blind, placebo-controlled clinical investigation. The objective of the study is to confirm the efficacy of Multi-Gyn ActiGel Plus to treat BV as compared to a placebo control.
- Trial name
- NCT04807842
- Testing
- vaginal gel
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- BioClin BV
HIV-1-infection
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects
Open-label, randomized, parallel-group, comparative study of pharmacokinetics and bioequivalence of VM-1500FDC (elsulfavirine/emtricitabine/tenofovir fixed-dose combination) and Elpida® with Truvada® (emtricitabine/tenofovir)…
- Trial name
- NCT03706924
- Testing
- VM-1500FDC, Elpida®, Truvada®
- Where
- 2 sites in Russia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Viriom
Human Immunodeficiency Virus
Evaluation of Kaletra Therapy Over the Long-term
Long term observation of patients under lopinavir/ritonavir containing therapy
- Trial name
- NCT01083810
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 90 sites in Germany
- Volunteers
- 284 people
- Sponsor
- Abbott
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cytomegalovirus Retinitis, HIV Infections
A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS
To compare the time to progression of CMV retinitis between oral ganciclovir and IV ganciclovir during 20 weeks of maintenance treatment.
- Trial name
- NCT00002257
- Testing
- Ganciclovir
- Where
- 13 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.
- Trial name
- NCT00046332
- Testing
- GW810781
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00474370
- Testing
- Vicriviroc
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, HIV Infections
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends.
- Trial name
- NCT00267527
- Testing
- CJC 1295
- Volunteers
- 120 people
- Sponsor
- ConjuChem
Infections, Papillomavirus
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
This is an observational cohort study to assess the risk of autoimmune disease(s) within 12 months of receiving the first dose of Cervarix® in the exposed cohort and over a comparable period in the unexposed cohorts.
- Trial name
- NCT01953822
- Testing
- Data collection
- Volunteers
- 1,053 people
- Sponsor
- GlaxoSmithKline
HIV Infections, HIV-1
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
Approximately 36 HIV-negative women, aged >18 and < 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving dapivirine gel versus placebo.
- Trial name
- NCT00309205
- Testing
- dapivirine (TMC120) vaginal gel
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
- Trial name
- NCT00002287
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Glaxo Wellcome
Infections, Papillomavirus
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00456807
- Testing
- Cervarix TM
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus, HIV Infections
Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment
GSK1265744 (744) is an integrase strand transfer inhibitor (INSTI) currently in development for both the treatment and prevention of human immunodeficiency virus (HIV) infection.
- Trial name
- NCT02354937
- Testing
- GSK1265744 30 mg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- ViiV Healthcare
HIV Infections
The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
To assess the effects of two doses of synthetic peptide construction 3 ( SPC3 ) on HIV-1 plasma levels (as measured by RNA PCR Amplicor) and on lymphocyte subsets in patients with initial viral load above 10,000 copies/ml.
- Trial name
- NCT00002363
- Testing
- Peptide Construction 3, Synthetic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia Research Laboratories
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Vaginal Candida
Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)
Researchers already did trials that showed Empecid L Cream worked for patients with Vaginal yeast infection who were in those trials.
- Trial name
- NCT03599323
- Testing
- Clotrimazole 1% (Empecid L Cream, BAYB5097)
- Where
- Japan
- Volunteers
- 1,033 people
- Sponsor
- Bayer
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.